Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20303452 | 0.83 | EPAS1 (0.44) | MAPTFFAR4EPAS1GRIN2BTRPV1 | |
| SCHEMBL16373805 | 0.82 | FFAR4 (0.44) | MAPTFFAR4TRPV1SLC6A4CNR2 | |
| SCHEMBL21266901 | 0.82 | FFAR4 (0.41) | MAPTFFAR4GRIN2BTRPV1MEN1 | |
| SCHEMBL24459310 | 0.82 | FFAR4 (0.41) | MAPTFFAR4GRIN2BTRPV1MEN1 | |
| SCHEMBL4468349 | 0.82 | CCR5 (0.42) | MAPTFFAR4GRIN2BTRPV1MEN1 | |
| SCHEMBL16958568 | 0.80 | FFAR4 (0.43) | FFAR4EPAS1GRIN2BIDO1SLC6A4 | |
| SCHEMBL16952941 | 0.80 | GPR3 (0.42) | MAPTFFAR4MEN1HTTKMT2A | |
| SCHEMBL7364503 | 0.79 | MAPT (0.58) | MAPTEPAS1PTGDR2MEN1USP2 | |
| SCHEMBL10562329 | 0.79 | FFAR4 (0.45) | MAPTFFAR4PTGDR2GRIN2BTRPV1 | |
| SCHEMBL28758197 | 0.79 | FFAR4 (0.47) | MAPTFFAR4PTGDR2TRPV1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3558298-B1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-10968232-B2 | Antidiabetic spirochroman compounds | MERCK SHARP & DOHME CORP. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
| EP-3750890-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Fudan University (CN) | 2020-12-16 | — | — | EP | disclosed |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2019-11-07 | — | — | US | disclosed |
| EP-3558298-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2019-10-30 | — | — | EP | disclosed |
| WO-2019154047-A1 | ALKOXYBENZO-FIVE-MEMBERED (SIX-MEMBERED) HETEROCYCLIC AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | 复旦大学 | 2019-08-15 | — | — | WO | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| WO-2018118670-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601714-B2 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BARBOSA ANTONIO J M | 2008-11-20 | — | — | US | disclosed |
| EP-1765791-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006014482-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287410-A1 | PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA | PRKCZ, PRKCQ, PRKCH | MAPT 3483/4885FFAR4 2608/4885EPAS1 1749/4885 |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MAPT 4637/4885FFAR4 3254/4885EPAS1 1414/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MAPT 4637/4885FFAR4 3254/4885EPAS1 1414/4885 |
| US-10968232-B2 | Antidiabetic spirochroman compounds | GPR119, GPR52, GPR55 | MAPT 4627/4885FFAR4 23/4885EPAS1 850/4885 |
| US-20190337961-A1 | ANTIDIABETIC SPIROCHROMAN COMPOUNDS | GPR119, GPR52, GPR55 | MAPT 4627/4885FFAR4 23/4885EPAS1 850/4885 |
| US-20060025433-A1 | Pyrimidine derivatives useful as inhibitors of PKC-theta | PRKCZ, PRKCQ, PRKCH | MAPT 3483/4885FFAR4 2608/4885EPAS1 1749/4885 |
| US-20210032230-A1 | Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof | LIPC, GPR119, VIP | MAPT 3241/4885FFAR4 502/4885EPAS1 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.